

! FINDPATTERNS on geneseq.* allowing 0 mismatches			
!	1	HAEGTFTSDVSSYLEGQAQAEFIAWLVNG (K) {1,9}R	January 3
!	2	HSEGTFTSDVSSYLEGQAQAEFIAWLVNG (K) {1,9}R	
!	3	HAEGTFTSDVSSYLEGQAQAEFIAWLVNG (K) {1,9}R	
!	4	HSEGTFTSDVSSYLEGQAQAEFIAWLVNG (K) {1,9}R	
2	ADO44524	ck: 7606 len: 35 ! Ado44524 Human GLP-1 peptide derivative 8S-	
		HSEGTFTSDVSSYLEGQAQAEFIAWLVNG (K) {1,9}R	
	1:	HSEGTFTSDVSSYLEGQAQAEFIAWLVNGK {5}R	
		HSEGTFTSDVSSYLEGQAQAEFIAWLVNGKKKKR	
2	ADO44525	ck: 3095 len: 37 ! Ado44525 Human GLP-1 peptide derivative 8S-	
		HSEGTFTSDVSSYLEGQAQAEFIAWLVNG (K) {1,9}R	
		HSEGTFTSDVSSYLEGQAQAEFIAWLVNGK {7}R	
	1:	HSEGTFTSDVSSYLEGQAQAEFIAWLVNGKKKKKKR	
2	ADO44523	ck: 2417 len: 33 ! Ado44523 Human GLP-1 peptide derivative 8S-	
		HSEGTFTSDVSSYLEGQAQAEFIAWLVNG (K) {1,9}R	
		HSEGTFTSDVSSYLEGQAQAEFIAWLVNGK {3}R	
	1:	HSEGTFTSDVSSYLEGQAQAEFIAWLVNGKKR	
2	ADO44521	ck: 7528 len: 31 ! Ado44521 Human GLP-1 peptide derivative 8S-	
		HSEGTFTSDVSSYLEGQAQAEFIAWLVNG (K) {1,9}R	
		HSEGTFTSDVSSYLEGQAQAEFIAWLVNGK	
	1:	HSEGTFTSDVSSYLEGQAQAEFIAWLVNGK	
4	ADO44532	ck: 7810 len: 35 ! Ado44532 Human GLP-1 peptide derivative 8S-	
		HSEGTFTSDVSSYLEGQAQAEFIAWLVNG (K) {1,9}R	
		HSEGTFTSDVSSYLEGQAQAEFIAWLVNGK {5}R	
	1:	HSEGTFTSDVSSYLEGQAQAEFIAWLVNGKKKKR	
2	ADO44522	ck: 9935 len: 32 ! Ado44522 Human GLP-1 peptide derivative 8S-	
		HSEGTFTSDVSSYLEGQAQAEFIAWLVNG (K) {1,9}R	
		HSEGTFTSDVSSYLEGQAQAEFIAWLVNGK {2}R	
	1:	HSEGTFTSDVSSYLEGQAQAEFIAWLVNGKKR	

Databases searched:
EMBL, Release 8.0, Released on 4Apr2006, Formatted on 29Apr2006

Total finds: 6
Total length: 457,216,429
Total sequences: 2,589,679
CPU time: 34:55.55

!!AA SEQUENCE 1.0
ID ADO44521 standard; peptide; 31 AA.
XX AC ADO44521;
XX DT 29-JUL-2004 (first entry)
XX DE Human GLP-1 peptide derivative 8S-des36R-GLPI+1KR.
XX KW GLP-1; glucagon-like peptide 1; dipeptidylpeptidase IV; trypsin;
XX KW antidiabetic; anorectic; insulin secretion.
XX OS Homo sapiens.
XX OS Synthetic.
XX FT Key Location/Qualifiers
FT Modified-site 31
FT /note= "C-terminal amide"
XX PN WO2004037859-A1.
XX PD 06-MAY-2004.
XX PF 10-OCT-2003; 2003WO-JP013020.
XX PR 11-OCT-2002; 2002JP-00299283.
XX PA (SANW) SANWA KAGAKU KENKYUSHO CO LTD.
XX PI Hayashi Y, Makino M, Kouzaki T, Takeda M, Jomori T;
XX DR WPI; 2004-357426/33.
XX PT New glucagon-like peptide 1 derivatives comprising an added C-terminal
PT peptide, with improved transmembrane absorbability used for the treatment
XX of diabetes.
XX PS Example 1; SEQ ID NO 12; 48pp; Japanese.
XX CC The invention relates to peptides consisting of a sequence derived from
CC glucagon-like peptide 1 (GLP-1) residues 7-35 by addition, deletion
CC and/or substitution of one or more amino acid residues. The GLP-1 derived
CC peptides have an added sequence at the C-terminal of formula Waa-(Xaa)n-
CC Yaa, where Waa is arginine or lysine; Xaa is arginine or lysine; Yaa is
CC arginine, arginine amide, lysine, lysine amide or homoserine; and n is 0-
CC 14. The GLP-1 peptide derivatives have tolerance to dipeptidylpeptidase
CC IV and to trypsin due to the nature of the substitution. The peptides can
CC be synthesised by standard solid-state peptide synthesis methods. The
CC peptides can be used in the treatment of diabetes (insulin-dependent or
CC insulin non-dependent), obesity and excessive appetite. Sequences
CC ADO44512-ADO44534 represent examples of GLP-1 peptide derivatives.
XX SQ Sequence 31 AA;

ADO44521 Length: 31 January 31, 2007 15:59 Type: P Check: 7528 ..

1 HSEGTFTSDV SSVLEGGQAAK EPIAWLVK GK R

!!AA SEQUENCE 1.0
ID ADO44522 standard; peptide; 32 AA.
XX
AC ADO44522;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human GLP-1 peptide derivative 8S-des36R-GLP1+2KR.
XX
KW GLP-1; glucagon-like peptide 1; dipeptidylpeptidase IV; trypsin;
XX antidiabetic; anorectic; insulin secretion.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 32
FT /note= "C-terminal amide"
XX
PN W02004037859-A1.
XX
XX 06-MAY-2004.
XX
PF 10-OCT-2003; 2003WO-JP013020.
XX
PR 11-OCT-2002; 2002JP-00299283.
XX
XX (SANW) SANWA KAGAKU KENKYUSHO CO LTD.
XX
PI Hayashi Y, Makino M, Kouzaki T, Takeda M, Jomori T;
XX
DR WPI; 2004-357426/33.
XX
XX New glucagon-like peptide 1 derivatives comprising an added C-terminal
PT peptide, with improved transmucosal absorbability used for the treatment
PT of diabetes.
XX
XX Example 1; SEQ ID NO 13; 48pp; Japanese.
XX
XX The invention relates to peptides consisting of a sequence derived from
CC glucagon-like peptide 1 (GLP-1) residues 7-35 by addition, deletion
CC and/or substitution of one or more amino acid residues. The GLP-1 derived
CC peptides have an added sequence at the C-terminal of formula Waa-(Xaa)n-
CC Yaa, where Waa is arginine or lysine; Xaa is arginine or lysine; Yaa is
CC arginine, arginine amide, lysine, lysine amide or homoserine; and n is 0-
CC 14. The GLP-1 peptide derivatives have tolerance to dipeptidylpeptidase
CC IV and to trypsin due to the nature of the substitution. The peptides can
CC be synthesised by standard solid-state peptide synthesis methods. The
CC peptides can be used in the treatment of diabetes (insulin-dependent or
CC insulin non-dependent), obesity and excessive appetite. Sequences
CC ADO44512-ADO44534 represent examples of GLP-1 peptide derivatives.
XX
SQ Sequence 32 AA;

ADO44522 Length: 32 January 31, 2007 15:58 Type: P Check: 9935 ..

1 HSEGTFTSDV SSYLEGQAAK EPIAWVKGK KR

!!AA_SEQUENCE 1.0
ID ADO44523 standard; peptide; 33 AA.
XX AC ADO44523;
XX DT 29-JUL-2004 (first entry)
XX DE Human GLP-1 peptide derivative 8S-dee36R-GLP1+3KR.
XX KW GLP-1; glucagon-like peptide 1; dipeptidylpeptidase IV; trypsin;
XX KW antidiabetic; anorectic; insulin secretion.
XX OS Homo sapiens.
XX OS Synthetic.
XX FH Key Location/Qualifiers
FT Modified-site 33
FT /note= "C-terminal amide"
XX PN WO2004037859-A1.
XX PD 06-MAY-2004.
XX PF 10-OCT-2003; 2003WO-JP013020.
XX PR 11-OCT-2002; 2002JP-00299283.
XX PA (SANW) SANWA KAGAKU KENKYUSHO CO LTD.
XX PI Hayashi Y, Makino M, Kouzaki T, Takeda M, Jomori T;
XX DR WPI; 2004-357426/33.
XX PT New glucagon-like peptide 1 derivatives comprising an added C-terminal
PT peptide, with improved transmemucosal absorability used for the treatment
XX of diabetes.
XX PS Example 1; SEQ ID NO 14; 48pp; Japanese.
XX CC The invention relates to peptides consisting of a sequence derived from
CC glucagon-like peptide 1 (GLP-1) residues 7-35 by addition, deletion
CC and/or substitution of one or more amino acid residues. The GLP-1 derived
CC peptides have an added sequence at the C-terminal of formula Waa-(Xaa)n-
CC Yaa, where Waa is arginine or lysine; Xaa is arginine or lysine; Yaa is
CC arginine, arginine amide, lysine, lysine amide or homoserine; and n is 0-
CC 14. The GLP-1 peptide derivatives have tolerance to dipeptidylpeptidase
CC IV and to trypsin due to the nature of the substitution. The peptides can
CC be synthesised by standard solid-state peptide synthesis methods. The
CC peptides can be used in the treatment of diabetes (insulin-dependent or
CC insulin non-dependent), obesity and excessive appetite. Sequences
CC ADO44512-ADO44534 represent examples of GLP-1 peptide derivatives.
XX SQ Sequence 33 AA;

ADO44523 Length: 33 January 31, 2007 15:59 Type: P Check: 2417 ..

1 HSEGTFTSDV SSYLEGQAAK EFIAWLKVKK KKR

!!AA SEQUENCE 1.0
ID ADO44524 standard; peptide; 35 AA.
XX AC ADO44524;
XX DT 29-JUL-2004 (first entry)
XX DE Human GLP-1 peptide derivative 8S-des36R-GLP1+5KR.
XX KW GLP-1; glucagon-like peptide 1; dipeptidylpeptidase IV; trypsin;
XX KW antidiabetic; anorectic; insulin secretion.
XX OS Homo sapiens.
XX OS Synthetic.
XX PH Key Location/Qualifiers
FT Modified-site 35
FT /note= "C-terminal amide"
XX PN WO2004037859-A1.
XX PD 06-MAY-2004.
XX PF 10-OCT-2003; 2003WO-JP013020.
XX PR 11-OCT-2002; 2002JP-00299283.
XX PA (SANW) SANWA KAGAKU KENKYUSHO CO LTD.
XX PI Hayashi Y, Makino M, Kouzaki T, Takeda M, Jomori T;
XX DR WPI; 2004-357426/33.
XX PT New glucagon-like peptide 1 derivatives comprising an added C-terminal
XX PT peptide, with improved transmucosal absorbability used for the treatment
XX PT of diabetes.
XX PS Example 1; SEQ ID NO 15; 48pp; Japanese.
XX CC The invention relates to peptides consisting of a sequence derived from
XX CC glucagon-like peptide 1 (GLP-1) residues 7-35 by addition, deletion
XX CC and/or substitution of one or more amino acid residues. The GLP-1 derived
XX CC peptides have an added sequence at the C-terminal of formula Waa-(Xaa)n-
XX CC Yaa, where Waa is arginine or lysine; Xaa is arginine or lysine; Yaa is
XX CC arginine, arginine amide, lysine, lysine amide or homoserine; and n is 0-
XX CC 14. The GLP-1 peptide derivatives have tolerance to dipeptidylpeptidase
XX CC IV and to trypsin due to the nature of the substitution. The peptides can
XX CC be synthesised by standard solid-state peptide synthesis methods. The
XX CC peptides can be used in the treatment of diabetes (insulin-dependent or
XX CC insulin non-dependent), obesity and excessive appetite. Sequences
XX CC ADO44512-ADO44534 represent examples of GLP-1 peptide derivatives.
XX SQ Sequence 35 AA;

ADO44524 Length: 35 January 31, 2007 15:59 Type: P Check: 7606 ..

1 HSEGTFTSDV SSYLEGQAAK EFIAWLKKGK KKKKR

!!AA SEQUENCE 1.0
ID ADO44525 standard; peptide; 37 AA.
XX
AC ADO44525;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human GLP-1 peptide derivative 8S-des36R-GLPI+7RR.
XX
KW GLP-1; glucagon-like peptide 1; dipeptidylpeptidase IV; trypsin;
XX antidiabetic; anorectic; insulin secretion.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 37
FT /note= "C-terminal amide"
XX
FN WO2004037859-A1.
XX
XX 06-MAY-2004.
XX
XX 10-OCT-2003; 2003WO-JP013020.
XX
XX 11-OCT-2002; 2002JP-00299283.
XX
XX (SANW) SANWA KAGAKU KENKYUSHO CO LTD.
XX
XX Hayashi Y, Makino M, Kouzaki T, Takeda M, Jonori T;
XX
XX WPI; 2004-357426/33.
XX
XX New glucagon-like peptide 1 derivatives comprising an added C-terminal
XX peptide, with improved transmemucosal absorability used for the treatment
XX of diabetes.
XX
XX Example 1; SEQ ID NO 16; 48pp; Japanese.
XX
XX The invention relates to peptides consisting of a sequence derived from
XX glucagon-like peptide 1 (GLP-1) residues 7-35 by addition, deletion
XX and/or substitution of one or more amino acid residues. The GLP-1 derived
XX peptides have an added sequence at the C-terminal of formula Waa-(Xaa)n-
XX Yaa, where Waa is arginine or lysine; Xaa is arginine or lysine; Yaa is
XX arginine, arginine amide, lysine, lysine amide or homoserine; and n is 0-
XX 14. The GLP-1 peptide derivatives have tolerance to dipeptidylpeptidase
XX IV and to trypsin due to the nature of the substitution. The peptides can
XX be synthesised by standard solid-state peptide synthesis methods. The
XX peptides can be used in the treatment of diabetes (insulin-dependent or
XX insulin non-dependent), obesity and excessive appetite. Sequences
XX ADO44512-ADO44534 represent examples of GLP-1 peptide derivatives.
XX
SQ Sequence 37 AA;

ADO44525 Length: 37 January 31, 2007 15:59 Type: P Check: 3095 ..

1 HSEGTFTSDV SSVLEQQAANK EFIAMLVK GK KKKKKR

!!IAA SEQUENCE 1.0
XX ID ADO44532 standard; peptide; 35 AA.
XX AC ADO44532;
XX DT 29-JUL-2004 (first entry)
XX DE Human GLP-1 peptide derivative 8S26Q34N-des36R-GLP1-5KR.
XX KW GLP-1; glucagon-like peptide 1; dipeptidylpeptidase IV; trypsin;
XX KW antidiabetic; anorectic; insulin secretion.
XX OS Homo sapiens.
XX OS Synthetic.
XX FH Key Location/Qualifiers
FT Modified-site 35
FT /note= "C-terminal amide"
XX PN WO2004037859-A1.
XX PD 06-MAY-2004.
XX PF 10-OCT-2003; 2003WO-JP013020.
XX PR 11-OCT-2002; 2002JP-00299283.
XX PA (SANW) SANWA KAGAKU KENKYUSHO CO LTD.
XX PI Hayashi Y, Makino M, Kouzaki T, Takeda M, Jomori T;
XX DR WPI; 2004-357426/33.
XX PT New glucagon-like peptide 1 derivatives comprising an added C-terminal
XX PT peptide, with improved transmucosal absorability used for the treatment
XX PT of diabetes.
XX PS Example 1; SEQ ID NO 23; 48pp; Japanese.
XX CC The invention relates to peptides consisting of a sequence derived from
XX CC glucagon-like peptide 1 (GLP-1) residues 7-35 by addition, deletion
XX CC and/or substitution of one or more amino acid residues. The GLP-1 derived
XX CC peptides have an added sequence at the C-terminal of formula Waa-(Xaa)n-
XX CC Yaa, where Waa is arginine or lysine; Xaa is arginine or lysine; Yaa is
XX CC arginine, arginine amide, lysine, lysine amide or homoserine; and n is 0-
XX CC 14. The GLP-1 peptide derivatives have tolerance to dipeptidylpeptidase
XX CC IV and to trypsin due to the nature of the substitution. The peptides can
XX CC be synthesised by standard solid-state peptide synthesis methods. The
XX CC peptides can be used in the treatment of diabetes (insulin-dependent or
XX CC insulin non-dependent), obesity and excessive appetite. Sequences
XX CC ADO44512-ADO44534 represent examples of GLP-1 peptide derivatives.
XX SQ Sequence 35 AA;

ADO44532 Length: 35 January 31, 2007 15:59 Type: P Check: 7810 ..

1 HSEGTFTSDV SSYLEGQAAQ EFIAVLVNGK KKKKR

! FINDPATTERNS on /pir: * allowing 0 mismatches

! 1 HAEGTFTSDVSSYLEGQAAKEFIAMLVKG(K){1,9}R
! 2 HSEGTFTSDVSSYLEGQAAKEFIAMLVKG(K){1,9}R
! 3 HAEGTFTSDVSSYLEGQAAKEFIAMLVNG(K){1,9}R
! 4 HSEGTFTSDVSSYLEGQAAKEFIAMLVNG(K){1,9}R

January 3

Databases searched:

NBRF, Release 80.0, Released on 31Dec2004, Formatted on 21Jun2005

Total finds: 0
Total length: 96,216,763
Total sequences: 283,416
CPU time: 06:13.12

! FINDPATTERNS on (uniprot:* allowing 0 mismatches

! 1 HAEGTFTSDVSSYLEGQAQAEFIWLKVG (K) {1,9}R
! 2 HSEGTFTSDVSSYLEGQAQAEFIWLKVG (K) {1,9}R
! 3 HAEGTFTSDVSSYLEGQAQAEFIWLKVG (K) {1,9}R
! 4 HSEGTFTSDVSSYLEGQAQAEFIWLKVG (K) {1,9}R

January 3

Databases searched:

UNIPROT, Release 7.2, Released on 7Mar2006, Formatted on 7Mar2006

Total finds: 0
Total length: 925,015,592
Total sequences: 2,849,598
CPU time: 1:01:19.41